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Abstract. There is a critical unmet need for reliable markers of disease and disease course in mild cognitive impairment
(MCI) and early Alzheimer’s disease (AD). The growing appreciation of the importance of inflammation in early AD has
focussed attention on inflammatory biomarkers in cerebrospinal fluid or plasma; however, non-specific inflammation markers
have disappointed to date. We have adopted a targeted approach, centered on an inflammatory pathway already implicated
in the disease. Complement, a core system in innate immune defense and potent driver of inflammation, has been implicated
in pathogenesis of AD based on a confluence of genetic, histochemical, and model data. Numerous studies have suggested
that measurement of individual complement proteins or activation products in cerebrospinal fluid or plasma is useful in
diagnosis, prediction, or stratification, but few have been replicated. Here we apply a novel multiplex assay to measure five
complement proteins and four activation products in plasma from donors with MCI, AD, and controls. Only one complement
analyte, clusterin, differed significantly between control and AD plasma (controls, 295 mg/l; AD, 388 mg/l: p < 10−5). A
model combining clusterin with relevant co-variables was highly predictive of disease. Three analytes (clusterin, factor I,
terminal complement complex) were significantly different between MCI individuals who had converted to dementia one
year later compared to non-converters; a model combining these three analytes with informative co-variables was highly
predictive of conversion. The data confirm the relevance of complement biomarkers in MCI and AD and build the case for
using multi-parameter models for disease prediction and stratification.
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INTRODUCTION26
The current lack of plasma biomarkers for diag-27
nosis, stratification, or prediction of outcome in AD28
is a major deficit that compromises early diagno-29
sis and patient selection for trials of novel therapies30
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[1–3]. In particular, biomarkers that aid early diagno- 31
sis and/or predict progression from MCI to AD are a 32
critical need. Primarily of value in the near future to 33
aid in the recruitment to secondary prevention trials, 34
such markers predictive of progression in prodro- 35
mal states might become of clinical value in future 36
as disease modification therapies become available. 37
A few plasma markers have been described but are 38
untested in preclinical disease and likely unsuitable 39
for early diagnosis [3]. The goal for current studies is 40
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to deliver a highly informative plasma biomarker or41
set of markers that enable early diagnosis and predict42
disease course [4, 5]. The recognition that inflamma-43
tion is an important player in AD and likely an early44
event in disease pathogenesis brings to the fore the45
potential use of markers of inflammation [6]. Non-46
specific indicators of peripheral inflammation such as47
C-reactive protein and inflammatory cytokines have48
proved unreliable as markers of disease or disease49
progression [7, 8], suggesting that a more targeted50
approach, focusing on specific inflammatory path-51
ways might be more rewarding.52
Complement, a pillar of innate immunity and key53
player in driving inflammatory responses to injury54
and infection, is a prime target pathway, implicated55
in the pathogenesis of AD through genetic, patho-56
logical, and animal model evidence [9–11]. Several57
published studies have explored whether plasma58
levels of complement components, regulators, or59
activation products are altered in AD or predict pro-60
gression in the disease. In one of the first untargeted61
proteomics analyses of plasma in AD, complement62
factor H (FH) was found to be elevated in AD plasma63
compared to controls [1]; an intriguing observa-64
tion given the genetic association between FH and65
age-related macular degeneration (AMD), another66
amyloid related condition [12, 13]. However, one67
other targeted study using a different methodology68
did not find association of FH with AD [14], and69
the common polymorphism in FH (Y402H) that is a70
strong risk for AMD does not significantly impact AD71
risk when assessed at the genetic level [15, 16]. Levels72
of plasma clusterin, a modulator of the terminal com-73
plement pathway, have been associated with disease,74
disease subtype, and rate of progression in several75
studies [17–20], although as with FH, negative find-76
ings have also been reported [21]. Plasma factor I (FI),77
measured semi-quantitatively, was highly predictive78
of brain atrophy in AD [22]. C1s and C9 have been79
implicated at the genetic level in pathway analysis80
studies [23].81
We used these published findings, together with82
relevant genetic data, to identify a candidate com-83
plement biomarker set. Here we describe the use84
of a custom-made ten-analyte multiplex set on85
the MSD platform to measure selected candidate86
AD biomarker complement proteins and activation87
products. The set comprised FH (measured as the88
individual Y402 and H402 alleles [22]), clusterin, FI,89
C1s, C9, C4d, Bb, iC3b, and TCC. The four comple-90
ment activation products selected for measurement91
included markers of classical (C4d, iC3b), alternative92
(Bb, iC3b), and terminal (terminal complement com- 93
plex; TCC) pathway activation. The study comprised 94
two arms, one in which AD samples were compared 95
to matched controls, and the other in which enrol- 96
ment samples from individuals with MCI who had 97
subsequently converted to AD when re-assessed 12 98
months later (convertors) or who had remained sta- 99
ble over the period of assessment (non-convertors) 100
were compared. Of the analytes measured, only clus- 101
terin differed significantly between matched controls 102
and AD patients, while three analytes, clusterin, FI, 103
and TCC, differed significantly between MCI conver- 104
tors and non-convertors. For each study arm, models 105
were built comprising the analytes that differed sig- 106
nificantly together with relevant co-variables (APOE 107
status, age). Each of the models was highly predic- 108
tive with overall predictive power (from area under 109
the curve [AUC] in receiver-operating characteristic 110
[ROC] analysis) of 0.78 for AD versus control and 111
0.85 for MCI convertor versus non-convertor. 112
The findings further implicate complement as 113
a contributor to disease progression in AD and 114
make the case for building multi-parameter models 115
including informative complement biomarkers, non- 116
complement biomarkers and other patient data that 117
enable patient stratification and prediction of progres- 118
sion. 119
MATERIALS AND METHODS 120
Samples 121
All samples were first visit samples obtained from 122
the previously reported AddNeuroMed and Dementia 123
Case Register studies [24, 25]. For comparison of AD 124
and control groups, a total of 292 first visit samples 125
(106 AD, 186 controls) were selected. The mean age 126
for the AD samples was 74.7 years and mean age of 127
controls was 78.1 years. The sample set was randomly 128
divided into a training set comprising 206 samples (75 129
AD, 131 controls) to generate the model, and a test- 130
ing set comprising 86 samples (31 AD, 55 controls) to 131
assess the accuracy of the model. In a separate anal- 132
ysis, 189 samples obtained from patients diagnosed 133
with MCI at the point of sampling were tested. Note 134
that all measurements here were on this first sample 135
when all were classified as MCI. Upon re-assessment 136
12 months later, 49 of these patients had converted to 137
AD while 140 had not converted. The mean age at 138
first presentation was 75.2 years for the convertors 139
and 76.3 years for non-convertors. These 189 MCI 140
samples were randomly divided into a training set of 141
Un
co
rre
cte
d A
uth
or
 P
ro
of
S. Hakobyan et al. / Complement Biomarkers in Alzheimer’s Disease 3
133 (98 not converted, 35 converted), and testing set142
of 56 (42 not converted, 14 converted) for analysis.143
Assay development and multiplexing144
Ten complement analytes were selected for this145
study, six components or regulators (C1s, C9, clus-146
terin, FI, FH-Y402, FH-H402), and four activation147
products (iC3b, C4d, Bb and TCC). Analyte choice148
was informed by reference to previous studies of149
complement biomarkers in AD, and availability of150
reagents; the activation marker set was chosen to151
interrogate classical (C4d, iC3b), alternative (Bb,152
iC3b), and terminal (TCC) activation pathways. The153
FH-Y402 and FH-H402 allotypes were measured154
separately using highly specific monoclonal anti-155
bodies as described previously [26], and total FH156
concentration was obtained by summing the con-157
centrations of the two allotypes. For each analyte,158
an antibody pair was selected from commercial or159
in-house sources (Table 1) and tested in ELISA160
for capacity to detect the analyte in plasma using161
purified proteins as standards. Selected antibody162
pairs were then tested in single-plex assays using163
high-bind plates from “ELISA Conversion Pack I”164
(MesoScale Discovery Platform [MSD], Rockville,165
Maryland, USA). Detection antibodies were conju-166
gated to SULFO-TAG with ratio 1:12 according to the167
manufacturer’s instructions. Single-plex assays were168
validated for reproducibility (intra- and inter-assay169
Coefficient of Variation [CV] <10%), sensitivity and170
dynamic range. For each analyte the range of plasma171
dilutions that enabled accurate quantitation was172
assessed; the optimal plasma dilution for measure-173
ment of all analytes in the set was then selected.174
Ten-plex plates (all analytes measured in a single175
well) were then printed by MSD using the supplied176
capture antibodies, and re-validated for reproducibil-177
ity, sensitivity, and dynamic range and to confirm178
that all included analytes could be measured at a sin-179
gle plasma dilution. Ten-plex plates were also tested180
with mixtures of the analyte standards to ensure that181
there was no “cross-talk” between assays, an essen-182
tial quality control in multiplex assays, and CVs for183
each analyte re-tested.184
The assay protocol was as follows: Printed ten-185
plex plates were blocked with 150l/well 3% BSA186
in PBS at 4◦C overnight. Plasma samples were diluted187
1:300 in assay buffer (PBS containing 1% BSA and188
10 mM EDTA); 25l aliquots were then added in189
duplicate to wells. To calibrate the assays, a stan-190
dard plasma was generated comprising a mixture191
of normal plasma and complement-activated plasma 192
in which levels of all analytes were pre-calibrated 193
against pure proteins using the single-plex assays. A 194
calibration curve comprising a series of 5-fold dilu- 195
tions of the standard plasma (1:5 to 1:6250) was run 196
in duplicate on each plate. Two additional dilutions 197
of standard plasma (1:250, 1:2500) in duplicate were 198
used as inter-plate controls. Plates were incubated 199
while shaking at room temperature for 60 min. After 200
washing in PBS containing 0.01% Tween20, a mix- 201
ture of the relevant SULFO-TAG-labelled detection 202
antibodies diluted in assay buffer (1:100) was added 203
and incubated as before. After washing, 150l of 2x 204
reading buffer was added to each well and electro- 205
chemiluminescence (ECL) signal was immediately 206
registered in a Sector S600 plate reader (MSD). ECL 207
values in plasma samples were automatically con- 208
verted to analyte concentration by reference to the 209
calibration curve. 210
Statistical methods 211
All statistical analysis was conducted in R version 212
3.0.2. Correlation of individual analyte concentration 213
with age at time of sampling was tested using Pearson 214
correlation. 215
In both the AD:control comparison and the MCI 216
convertor:non-convertor comparison, samples were 217
split into training and testing sets as described above 218
in order to reduce over-fitting of the model. Clustered 219
mixed-effects linear modeling (using the lme4 and 220
lmerTest R packages) was used to explore the asso- 221
ciations between analyte concentration and disease 222
status. Center of sampling was included as a random 223
effects variable, and complement analyte, APOE-4 224
status (negative, heterozygous, homozygous), age at 225
onset, and gender included as fixed effects variables. 226
Variables that were found to be significant in the train- 227
ing set were retained in a refined model, which was 228
tested for accuracy by applying to the test group. AUC 229
was calculated, and ROC curves drawn to define the 230
predictive power of the model. 231
RESULTS 232
Complement protein assays are sensitive and 233
speciﬁc in multiplex formats 234
Each of the complement analyte assays translated 235
from ELISA, through single-plex to multiplex with- 236
out loss of performance as assessed by calculating 237
CVs for each analyte. All analytes were accurately 238
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Table 1
Antibody pairs for ELISA and multiplex. The table lists the antibody pairs used in the multiplex set and the sources of the antibod-
ies. Quidel, https://www.quidel.com/; Hycult, http://www.hycultbiotech.com/; Comptech, http://www.complementtech.com/; Millipore,
www.emdmillipore.com
Analyte/assay Capture antibody (source) Detection antibody (source)
C1s MM Anti-C1s (M81, Hycult) MM Anti-C1s (F33, in house)
C9 MM Anti-C9 (B7, in house) MM Anti-C9 (6D4, in house)
Clusterin RP Anti-Apolipoprotein J/Clusterin (AB825, Millipore) MM Anti-Clusterin (MBI-40, in house)
FH-Y MM Anti FH-Y402 (MBI-6, in house) MM Anti-FH (OX-24)
FH-H MM Anti FH-H402 (MBI-7, in house) MM Anti-FH (OX-24)
FI MM Anti-FI (7B5, in house) RP Anti-FI (in house)
C4d MM Anti-neo-C4d (A251, Quidel) MM Anti-C4d (A213, Quidel)
TCC MM Anti-neo-C9 (aE11, Hycult) MM Anti-C8 (E2, in house)
iC3b MM Anti-neo-iC3b (A209, Quidel) MM Anti-C3b (C3-30, in house)
Bb MM Anti-neo-Bb (A252, Quidel) MM Anti-FB (JC1, in house)
MM, mouse monoclonal antibody; RP, rabbit affinity purified polyclonal antibody. Neo denotes neoepitope-specific antibody.
Table 2
Correlation between complement analyte concentration and age at
time of sample. C9, FI, and TCC all showed a significant positive
correlation with age in the populations sampled
Analyte R2 o
C1s –0.016 0.82
C9 0.23 0.0009
FH 0.059 0.40
Clusterin –0.08 0.26
FI 0.13 0.07
TCC 0.17 0.02
iC3b –0.059 0.40
Bb –0.013 0.85
C4d 0.11 0.13
measured at a plasma dilution of 1:300. There was239
no detectable inter-assay interference between the240
different analytes in the multiplex and intra- and241
inter-assay, confirming the suitability of the assay242
sets chosen for multiplexing. CVs were < 10% for all243
analytes in the multiplex (data not shown).244
C9, FI and TCC levels correlate with age245
Correlation with donor age at sampling was tested246
for all complement analytes in the complete set of247
samples (Table 2). C9 levels showed a strong posi-248
tive correlation with donor age at time of sampling.249
Levels of FI and TCC demonstrated weak but signif-250
icant positive correlations with donor age at time of251
sampling. Other complement analytes did not signif-252
icantly correlate with donor age.253
Clusterin is the sole plasma complement254
biomarker that distinguishes AD from control255
Of the nine complement analytes measured (FH256
variants combined to give total FH), only one, clus-257
terin, was significantly different between AD and258
control populations (Table 3). The mean plasma clus-259
terin concentration in controls was 295 mg/l and in 260
AD was 388 mg/l, a highly significant difference 261
(p = 2.32 × 10−6). A model combining clusterin with 262
co-variables associated with AD (APOE status and 263
age) was highly predictive with an AUC of 0.66 for 264
the test set and 0.78 for the entire sample set (Table 3; 265
Fig. 1A). At 70% sensitivity, the predicted specificity 266
of the model was 75%. 267
Three complement analytes differentiate MCI 268
convertors from non-convertors 269
From the analysis of MCI convertors versus non- 270
convertors, three of the nine complement analytes 271
were significantly different between the groups: clus- 272
terin, TCC, and FI (Table 4; Fig. 1B). Of these, 273
clusterin was the most significant; the mean clus- 274
terin level in non-convertors was 309 mg/l and in 275
convertors was 418 mg/l. TCC was significantly 276
lower in MCI convertors compared to non-convertors 277
(0.7 mg/l versus 3.6 mg/l), while FI was signif- 278
icantly reduced in MCI convertors compared to 279
non-convertors (27.7 mg/l versus 50.7 mg/l; the lat- 280
ter identical to healthy controls). From these data, 281
a model was constructed combining clusterin, TCC, 282
and FI with the sole co-variable associated with MCI 283
conversion (APOE status); the model was highly pre- 284
dictive of conversion with an AUC of 0.85 for the 285
entire sample set (Table 4, Fig. 1B). At 80% sen- 286
sitivity, the predicted specificity of the model was 287
79%. 288
Measurement of FH Y402H allotypic variants 289
predicts progression in MCI 290
In the selected model, total FH concentration 291
was not significantly reduced in AD compared to 292
controls (335.3 mg/l versus 350.8 mg/l; Table 3) 293
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Table 3
Mixed effects linear model for complement analyte difference between AD and controls. Clustered mixed-effects linear modeling (using
the lme4 and lmerTest R packages) was used to explore the associations between each variable and disease status. The variables which were
most strongly associated with diagnosis (based on p value) were then combined into one model (final model). Any variables which were not
significant after inclusion in the model were discarded. Note that final model for AD versus controls comprises Clusterin, APOE4, and age
Initial Model AD (mean ± SD; mg/l) Controls (mean ± SD; mg/l)  (95% CI) p
C1s 102.2 ± 19.4 104.1 ± 20.4 –0.001 (–0.005 – 0.003) 0.54
C4d 3.8 ± 4.5 2.9 ± 6.2 0.014 (–0.017 – 0.05) 0.39
C9 52.0 ± 17.1 51.2 ± 14.8 0.001 (–0.003 – 0.006) 0.65
Clusterin 387.6 ± 113.9 295.0 ± 128.5 –0.001 (–0.002 – –0.0004) 2.32× 10−6
FI 51.5 ± 37.8 50.7 ± 38.9 0.001 (–0.002 – 0.004) 0.32
TCC 3.2 ± 4.3 2.8 ± 2.3 –0.016 (–0.043 – 0.011) 0.27
iC3b 1.8 ± 1.2 1.6 ± 1.1 0.003 (–0.062 – 0.068) 0.93
Bb 21.2 ± 9.3 18.7 ± 8.8 0.003 (–0.005 – 0.010) 0.51
FH 335.3 ± 81.0 350.8 ± 99.0 0.0004 (–0.0004 – 0.001) 0.34
Gender (male) –0.082 (–0.21 – 0.05) 0.23
APOE4 –0.12 (–0.23 – –0.008) 0.039
Age at sample –0.021 (–0.03 – –0.01) 4.75× 10−5
Final model AD versus control  (95% CI) p
Clusterin –0.001 (–0.002 – –0.0008) 8.1 × 10−7
APOE4 –0.13 (–0.2378 – –0.02) 0.02
Age at sample –0.02 (–0.03 – –0.01) 2.4 × 10−5
A B
Fig. 1. Receiver-operating characteristic (ROC) curves representing models which differentiate AD from controls (A) and MCI convertors
from non-convertors (B). ROC curves were drawn for the final models distinguishing AD from controls (A; clusterin and APOE4) and
MCI convertors from non-convertors (B; clusterin, FI, and TCC). The area under the curve (AUC) for the final model was calculated, and
compared to that for APOE4 alone. AUC was used to define the predictive power of the analyte or analyte set that comprised the model; the
predictive power of the model for distinguishing AD from controls was 0.78, and for predicting conversion was 0.85.
or in MCI convertors compared to non-convertors294
(297.9 mg/l versus 351.4 mg/l; Table 4). When the295
levels of the Y402 and H402 variants of FH, measured296
separately using variant-specific capture antibodies297
and corrected for allele number, were compared298
between AD and control groups, there was no signif-299
icant difference (Y variant, AD, 170.4 mg/l, controls,300
172.5 mg/l; H variant, AD, 167 mg/l, controls, 301
175.5 mg/l; Table 5). A similar analysis comparing 302
MCI mon-convertors and convertors revealed a sig- 303
nificantly lower level of the H variant in the convertors 304
(Y variant, non-convertors, 166.3 mg/l. convertors, 305
164.4 mg/l; H variant, non-convertors, 172.5 mg/l, 306
convertors, 142.1 mg/l; Table 5; p = 0.0056). 307
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Table 4
Mixed effects linear model for complement analyte difference between MCI convertors and non-convertors. Clustered mixed-effects linear
modeling (using the lme4 and lmerTest R packages) was used to explore the associations between each variable and disease status. The
variables which were most strongly associated with diagnosis (based on p value) were then combined into one model (final model). Any
variables which were not significant after inclusion in the model were discarded. Note that final model for conversion versus non-conversion
comprises Clusterin, FI, and TCC
Initial Model Converted to AD Not converted  (95% CI) p
(mean ± SD; mg/l) (mean ± SD; mg/l)
C1s 88.9 ± 15.1 103.2 ± 24.8 –0.003 (–0.006– 0.0009) 0.15
C4d 2.2 ± 2.1 3.6 ± 3.2 –0.017 (–0.042– 0.008) 0.18
C9 42.8 ± 16.6 50.5 ± 14.1 0.002 (–0.0027 – 0.006) 0.43
Clusterin 417.5 ± 88.5 308.7 ± 115.2 0.002 (0.001 – 0.002) 2.43× 10−7
FI 27.7 ± 7.9 50.7 ± 26.6 –0.006 (–0.009 – –0.002) 0.0025
TCC 0.7 ± 2.5 3.6 ± 3.4 –0.03 (–0.04 – –0.01) 0.0027
iC3b 1.7 ± 1.2 1.7 ± 0.9 0.02 (–0.05 – 0.08) 0.67
Bb 18.3 ± 9.3 18.4 ± 8.8 0.003 (–0.005 – 0.01) 0.51
FH 297.9 ± 75 351.4 ± 96.8 –0.0001 (–0.001 – 0.0008) 0.76
Gender (male) 0.11 (–0.02 – 0.24) 0.10
APOE-4 –0.02 (–0.11 – 0.08) 0.71
Age at sample 0.0004 (–0.009 – 0.01) 0.94
Final model convertor versus non-convertor  (95% CI) p
Clusterin 0.002 (0.001 – 0.002) 1.26 × 10−9
FI –0.006 (–0.009 – –0.003) 1.42 × 10−5
TCC –0.024 (–0.04 – –0.008) 0.005
Table 5
FH allotypes in AD and MCI. In an initial analysis there was no association between FH-Y402H genotype or diagnosis and FH plasma levels,
but plasma FH levels did predict whether patients convert from MCI to AD (by ANOVA, p = 0.00330. Allele number-corrected allotype
levels in FH-Y402H heterozygotes were then compared between AD and controls (top) and MCI non convertors and convertors (bottom);
FH-H402 levels were significantly lower (∗∗) in MCI patients who subsequently converted to AD when compared to those who did not
convert
FH allotype levels in AD and controls (mean ± SD; mg/l)
diagnosis Y402 H402 p
AD 170.4 ± 45.1 167.0 ± 39.8 0.71
control 172.5 ± 42.7 175.5 ± 38.2 0.71
p 0.81 0.26
FH allotype levels in MCI convertors and non-convertors (mean ± SD; mg/l)
converted Y402 H402 p
no 166.3 ± 47.2 172.5 ± 41.6 0.44
yes 164.4 ± 57.3 142.1 ± 34.5 0.18
p 0.90 0.0056∗∗
DISCUSSION308
A plasma marker or marker set that is indica-309
tive of pathology or predictive of conversion to310
AD in individuals with MCI, or disease course in311
patients with early AD is sorely needed to facilitate312
early diagnosis and inform selection of participants313
into future clinical trials, particularly those target-314
ing immune system involvement and inflammation.315
The abundant evidence implicating inflammation,316
and specifically complement, in pathogenesis led317
us to explore the complement system as a source318
of biomarkers. Guided by literature evidence and319
reagent availability, we selected ten complement ana-320
lytes and designed a multiplex assay to measure all321
simultaneously. Our data demonstrate that clusterin322
alone among the analytes tested significantly differ- 323
entiated AD patients from matched controls, while 324
clusterin, FI, and TCC were all significantly differ- 325
ent between individuals with MCI who subsequently 326
either converted to AD or remained stable when re- 327
assessed at one year post-sampling. In our sample set, 328
26% of the MCI cases progressed to dementia at one 329
year; this is markedly higher than published annual 330
conversion rates, typically around 10%, although 331
considerable variation between sample sets has been 332
noted [27]. 333
Several published studies have reported elevated 334
plasma levels of clusterin in AD compared to con- 335
trols in diverse ethnic groups [17–20, 28–30]. Taken 336
together with our findings, these data demonstrate 337
that elevated plasma clusterin level is a robust marker 338
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for AD that is replicated across different assay plat-339
forms. In light of this, it is somewhat paradoxical that340
two disease-associated SNP in clusterin are reported341
to associate with decreased plasma levels [29, 30].342
Precisely how plasma clusterin levels impact disease343
risk remains uncertain. Clusterin is a multifunctional344
molecule, an inhibitor of the complement terminal345
pathway but also a professional molecular chaperone346
involved in clearance of debris [31]. Amyloid plaques347
in AD are richly decorated with clusterin and a role348
in clearance of amyloid has been proposed [32, 33].349
Clusterin has also been shown to reduce A42 toxicity350
in a rat model of AD [34].351
Association of plasma clusterin levels with rate of352
cognitive decline has been reported both in MCI and353
AD [17, 20, 24]; in each of these studies, higher354
clusterin levels predicted more rapid decline. Our355
data demonstrating substantially higher plasma clus-356
terin in MCI donors who subsequently convert to AD357
compared to non-convertors robustly support these358
findings and show that elevated plasma clusterin is359
a powerful predictor of progression. The functional360
basis of this association is problematic; if clusterin361
is involved in reducing A toxicity and accelerat-362
ing amyloid clearance, then increased plasma levels363
might be expected to restrict the development of364
pathology. It is possible that increased clusterin365
production, reflected in increased plasma levels, rep-366
resents a failed protective response to the disease367
process.368
TCC, a marker of complement terminal pathway369
activation, is present on neurons, plaques, and adja-370
cent blood vessels in AD brain [32–35]; fluid-phase371
TCC (also termed sC5b-9) has been measured in AD372
CSF [36], but plasma levels of TCC have not pre-373
viously been reported in AD or MCI. Plasma TCC374
levels were not different between AD and controls375
but were significantly lower in MCI donors who376
subsequently converted to AD compared to non-377
convertors; this finding is somewhat counterintuitive378
in that it implies lower levels of terminal pathway379
activation in the convertors despite clear evidence380
that the terminal pathway is abundantly activated in381
AD brain. We suggest that the demonstrated elevated382
levels of clusterin, an efficient inhibitor of the termi-383
nal pathway, in the convertor group might suppress384
terminal pathway activation and TCC generation in385
plasma. Notably, plasma levels of activation pathway386
products (iC3b, C4d, Bb) were not different between387
the groups, suggesting that any difference in central388
complement activation between MCI convertors and389
non-convertors was not reflected in the periphery.390
FI is the enzyme responsible for regulating the 391
activation pathway convertases; complement recep- 392
tor 1, linked through GWAS studies to AD [9, 37, 393
38], is the major cell-associated cofactor for FI- 394
mediated cleavage of C3b/C4b. Plasma FI has 395
previously been reported as a biomarker of brain 396
atrophy [22]. Here we show that plasma FI level was 397
significantly reduced in MCI convertors compared to 398
non-convertors (27.7 mg/l versus 50.7 mg/l; the latter 399
identical to healthy controls). Lower levels of FI will 400
impact capacity to control complement activation 401
once triggered and favor dysregulation [39]. 402
In the mixed effects linear models described here, 403
FH was not significantly different between AD 404
patients compared to controls (335.3 mg/l versus 350. 405
8 mg/l; Table 3) or between MCI convertors com- 406
pared to non-convertors (297.9 mg/l versus 351. 407
4 mg/l; Table 4). The common FH-Y402 H poly- 408
morphism is a major risk factor for AMD [12, 13], 409
but does not associate with AD in multiple studies 410
[14–16]. Here we separately measured plasma lev- 411
els of the products of the two allotypic variants and 412
showed that levels of the FH-H402 variant were sig- 413
nificantly lower in MCI donors who subsequently 414
converted to AD compared to non-convertors. These 415
data could be explained by decreased expression of 416
the FH-H402 allele in the convertor group or, more 417
likely, by increased consumption of the FH- H402 418
allotype protein in response to the disease in MCI 419
convertors. Differential binding of the different FH- 420
Y402 H allotypes at sites of pathology has previously 421
been described in the context of AMD [40], and our 422
unpublished data suggest preferential binding of the 423
FH-H402 allotype in AD brain. 424
From our data we generated two models. The first 425
compared AD patients with controls and included 426
clusterin with the co-variables age and APOE status; 427
ROC curves constructed from this set gave an AUC 428
of 0.78 for the entire set, considered “moderately 429
predictive” [41]. The second model compared MCI 430
convertors and non-convertors and included clusterin, 431
TCC, and FI with the sole co-variable associated with 432
MCI conversion (APOE status); ROC curves gave an 433
AUC of 0.85 for the entire sample set, considered 434
“highly predictive”. Although levels of the FH-H402 435
allotype were significantly predictive of MCI conver- 436
sion when measured in FH-Y402 H heterozygotes, 437
this variable was not included in the model because 438
it applied only to the subset of the population that 439
possessed one or more H402 alleles; nevertheless, 440
the data demonstrate that measuring plasma allotype 441
levels for a common complement polymorphism can 442
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help predict disease and raise the prospect that other443
complement polymorphisms might also be predic-444
tive, as is the case in AMD [12, 13].445
In summary, we show that combinations of com-446
plement biomarkers can aid diagnosis and prediction447
of outcome in MCI and AD. The results described448
were from an initial set of just ten complement ana-449
lytes and from these only one was predictive for450
distinguishing AD from controls and three for pre-451
dicting progression in MCI. Expanding the test set452
of complement biomarkers will add other predictive453
analytes that will strengthen the predictive power of454
the marker set and provide further information on pre-455
cisely how complement contributes to AD pathology.456
Adding in non-complement biomarkers will likely457
further strengthen and contribute to an optimum mul-458
tiplex for diagnosis and prediction of outcome. The459
demonstration that complement activation occurs in460
MCI and predicts conversion strengthens the case for461
testing anti-complement therapies in this group.462
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